Satoshi Hamauchi

1.1k total citations
71 papers, 697 citations indexed

About

Satoshi Hamauchi is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Otorhinolaryngology. According to data from OpenAlex, Satoshi Hamauchi has authored 71 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 30 papers in Surgery and 28 papers in Otorhinolaryngology. Recurrent topics in Satoshi Hamauchi's work include Head and Neck Cancer Studies (28 papers), Gastric Cancer Management and Outcomes (20 papers) and Oral health in cancer treatment (14 papers). Satoshi Hamauchi is often cited by papers focused on Head and Neck Cancer Studies (28 papers), Gastric Cancer Management and Outcomes (20 papers) and Oral health in cancer treatment (14 papers). Satoshi Hamauchi collaborates with scholars based in Japan, United States and Italy. Satoshi Hamauchi's co-authors include Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Akiko Todaka, Hirofumi Ogawa, Tetsuro Onitsuka, Takahiro Tsushima, Kentaro Yamazaki, Akira Fukutomi and Nozomu Machida and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Satoshi Hamauchi

60 papers receiving 688 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Satoshi Hamauchi Japan 17 360 266 234 191 156 71 697
Jarosław Kużdżał Poland 15 465 1.3× 301 1.1× 71 0.3× 37 0.2× 45 0.3× 65 861
Mayuko Ohuchi Japan 13 191 0.5× 313 1.2× 428 1.8× 19 0.1× 431 2.8× 31 878
Diclehan Ünsal Türkiye 10 98 0.3× 64 0.2× 128 0.5× 83 0.4× 99 0.6× 21 328
Tomohiro Kunishige Japan 13 210 0.6× 246 0.9× 254 1.1× 18 0.1× 99 0.6× 37 476
Wenyang Pang China 10 246 0.7× 287 1.1× 177 0.8× 15 0.1× 499 3.2× 14 750
Hiroshi Nakade Japan 13 207 0.6× 233 0.9× 245 1.0× 18 0.1× 99 0.6× 31 456
Jin Matsuyama Japan 15 715 2.0× 491 1.8× 328 1.4× 14 0.1× 153 1.0× 95 1.0k
Peigang Yang China 14 313 0.9× 210 0.8× 202 0.9× 11 0.1× 140 0.9× 58 650
Vincenzo Aiello‐Crocifoglio Mexico 11 248 0.7× 176 0.7× 306 1.3× 17 0.1× 61 0.4× 22 527
Jui‐Ying Lee Taiwan 15 379 1.1× 368 1.4× 162 0.7× 10 0.1× 69 0.4× 60 720

Countries citing papers authored by Satoshi Hamauchi

Since Specialization
Citations

This map shows the geographic impact of Satoshi Hamauchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoshi Hamauchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoshi Hamauchi more than expected).

Fields of papers citing papers by Satoshi Hamauchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoshi Hamauchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoshi Hamauchi. The network helps show where Satoshi Hamauchi may publish in the future.

Co-authorship network of co-authors of Satoshi Hamauchi

This figure shows the co-authorship network connecting the top 25 collaborators of Satoshi Hamauchi. A scholar is included among the top collaborators of Satoshi Hamauchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoshi Hamauchi. Satoshi Hamauchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Imaoka, Hiroshi, Masafumi Ikeda, Masato Ozaka, et al.. (2025). Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. European Journal of Cancer. 222. 115424–115424.
2.
Maron, Steven B., Keisho Chìn, Fadi S. Braiteh, et al.. (2025). Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers. ESMO Open. 10(11). 105806–105806.
3.
Muro, Kei, Keisho Chìn, Steven B. Maron, et al.. (2024). Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202.. Journal of Clinical Oncology. 42(16_suppl). 4046–4046. 2 indexed citations
4.
Yokota, Tomoya, et al.. (2024). Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer. Investigational New Drugs. 42(4). 361–368.
5.
Matsubayashi, Hiroyuki, Akiko Todaka, Takeshi Kawakami, et al.. (2022). Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients. Journal of Human Genetics. 68(2). 81–86. 7 indexed citations
6.
Todaka, Akiko, Hiroshi Nakase, Hiromichi Shirasu, et al.. (2022). Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study. Investigational New Drugs. 40(5). 1106–1116. 3 indexed citations
7.
Yokota, Tomoya, Satoshi Hamauchi, Yusuke Onozawa, et al.. (2022). Prognostic impact of the number of metastatic lymph nodes after surgery in locally advanced hypopharyngeal cancer. BMC Cancer. 22(1). 1101–1101. 6 indexed citations
8.
Yokota, Tomoya, Sadamoto Zenda, Ichiro Ota, et al.. (2021). Phase 3 Randomized Trial of Topical Steroid Versus Placebo for Prevention of Radiation Dermatitis in Patients With Head and Neck Cancer Receiving Chemoradiation. International Journal of Radiation Oncology*Biology*Physics. 111(3). 794–803. 19 indexed citations
9.
Hamauchi, Satoshi, Tomoya Yokota, Yusuke Onozawa, et al.. (2020). Chemoradiotherapy for high-risk stage II laryngeal cancer. International Journal of Clinical Oncology. 25(9). 1596–1603. 4 indexed citations
10.
11.
Kawakami, Takeshi, Takahiro Tsushima, Katsuhiro Omae, et al.. (2018). Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. BMC Cancer. 18(1). 573–573. 40 indexed citations
12.
Yokota, Tomoya, Satoshi Hamauchi, Yukio Yoshida, et al.. (2017). The phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for head and neck cancer patients. Annals of Oncology. 28. v391–v391. 1 indexed citations
13.
Shirasu, Hiromichi, Takahiro Tsushima, S. Kawai, et al.. (2017). Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer. 21(2). 338–344. 31 indexed citations
14.
15.
Kawakami, Takeshi, Nozomu Machida, Hirofumi Yasui, et al.. (2016). Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer. Cancer Chemotherapy and Pharmacology. 78(4). 809–814. 28 indexed citations
16.
Yokota, Tomoya, Hiroyuki Tachibana, Takashi Yurikusa, et al.. (2016). Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy. Supportive Care in Cancer. 24(7). 3029–36. 33 indexed citations
17.
Taniguchi, Hiroya, Yosuke Kito, Satoshi Hamauchi, et al.. (2015). 169P Serum CA19-9 response is an early predictive marker for the efficacy of regorafenib in refractory metastatic colorectal cancer. Annals of Oncology. 26. ix42–ix42.
18.
Hamauchi, Satoshi, Takahiro Tsushima, Akiko Todaka, et al.. (2015). Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy. Gastric Cancer. 19(3). 894–901. 5 indexed citations
19.
Yokota, Tomoya, Satoshi Hamauchi, Yoshiyuki Iida, et al.. (2014). Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer. Japanese Journal of Clinical Oncology. 45(2). 183–188. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jarosław Kużdżał Breakdown of academic impact, for papers by Mayuko Ohuchi Breakdown of academic impact, for papers by Diclehan Ünsal Breakdown of academic impact, for papers by Tomohiro Kunishige Breakdown of academic impact, for papers by Wenyang Pang Breakdown of academic impact, for papers by Hiroshi Nakade Breakdown of academic impact, for papers by Jin Matsuyama Breakdown of academic impact, for papers by Peigang Yang Breakdown of academic impact, for papers by Vincenzo Aiello‐Crocifoglio Breakdown of academic impact, for papers by Jui‐Ying Lee
Rankless by CCL
2026